Literature DB >> 21672329

Evaluation of diffusion-weighted magnetic resonance imaging and contrast-enhanced harmonic ultrasonography in detection and location of prostate transition-zone cancer.

R Wang1, J-J Chen, Y-C Zhou, M-M Huang, X-R Zhang, H-D Miao.   

Abstract

This retrospective study was designed to evaluate the value of contrast-enhanced harmonic ultrasonography (CEHU), diffusion-weighted magnetic resonance imaging (DW-MRI) and CEHU plus DW-MRI for the diagnosis of prostate transition-zone (TZ) cancer. In total, 31 TZ cancers in 28 patients and 25 peripheral zone (PZ) cancers in 21 patients without a TZ cancer were evaluated. All patients underwent DW-MRI and CEHU followed by radical prostatectomy. Predictors for the diagnosis of prostate cancer were evaluated in three protocols (CEHU, DW-MRI, CEHU plus DW-MRI). Statistical analysis of the differences between these protocols and receiver operating characteristic (ROC) curve analysis were carried out. CEHU plus DW-MRI had a significantly higher sensitivity, accuracy and negative-predictive value (90.3%, 73.2% and 81.3%, respectively) for TZ cancer than either method alone. The area under the ROC curve values were 0.659, 0.679 and 0.712 for CEHU, DW-MRI, and CEHU plus DW-MRI, respectively. In conclusion, CEHU plus DW-MRI might be a useful protocol for the detection and location of TZ cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21672329     DOI: 10.1177/147323001103900128

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  2 in total

1.  3-Tesla magnetic resonance imaging improves the prostate cancer detection rate in transrectral ultrasound-guided biopsy.

Authors:  Jie Chen; Xiao-Lei Yi; Li-Xin Jiang; Ren Wang; Jun-Gong Zhao; Yue-Hua Li; Bing Hu
Journal:  Exp Ther Med       Date:  2014-11-11       Impact factor: 2.447

2.  Diagnostic and prognostic values of contrast‑enhanced ultrasound combined with diffusion‑weighted magnetic resonance imaging in different subtypes of breast cancer.

Authors:  Gui-Feng Liu; Zong-Qiang Wang; Shu-Hua Zhang; Xue-Feng Li; Lin Liu; Ying-Ying Miao; Shao-Nan Yu
Journal:  Int J Mol Med       Date:  2018-03-27       Impact factor: 4.101

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.